Slawomir G. Kata
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Slawomir G. Kata has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Omar M. Aboumarzouk
Hamad Medical Corporation
3 shared publications Sarfraz Ahmad
Department of Urology, Ninewells Hospital and Medical School, Dundee, UK
2 shared publicationsAbdullah Zreik
NHS Greater Glasgow and Clyde, Glasgow, United Kingdom
1 shared publication- Abdullah Zreik
Department of Urology, NHS Greater Glasgow and Clyde, Glasgow, G51 4TF, Scotland, UK
1 shared publication - Bhaskar Kumar Somani
University Hospital Southampton NHS Trust, UK
1 shared publication Carol Goodman
The Scottish Photodynamic Therapy Centre, Ninewells Hospital & Medical School, Dundee, UK
1 shared publication
Latest Publications
- 1 March 2016
- Published by Elsevier in Photodiagnosis and Photodynamic Therapy
- Vol. 13, 255-260
Photodynamic diagnostic ureterorenoscopy: A valuable tool in the detection of upper urinary tract tumour
- 1 March 2016
- Published by Elsevier in Photodiagnosis and Photodynamic Therapy
- Vol. 13, 255-260
Photodynamic diagnostic ureterorenoscopy: A valuable tool in the detection of upper urinary tract tumour
- Open Access
- 1 January 2016
- Published by Polskie Towarzystwo Urologiczne in Central European Journal of Urology
- Vol. 69 (2) , 157-61
Are we closer to seeing carcinoma in situ in the upper urinary tract?
The Central European Journal of Urology is an open access quarterly-issued journal, which provides a forum for the presentation of original clinical, experimental and other research studies...
- 1 January 2016
- Published by Polskie Towarzystwo Urologiczne in Central European Journal of Urology
- Vol. 69 (2) , 157-61
Open AccessAre we closer to seeing carcinoma in situ in the upper urinary tract?
The Central European Journal of Urology is an open access quarterly-issued journal, which provides a forum for the presentation of original clinical, experimental and other research studies...
- Open Access
- 1 January 2016
- Published by Polskie Towarzystwo Urologiczne in Central European Journal of Urology
- Vol. 69 (4) , 334-340
Concurrent bladder cancer in patients undergoing photodynamic diagnostic ureterorenoscopy: how many lesions do we miss under white light cystoscopy?
There is an ongoing debate on panurothelial changes in the upper and lower urinary tract as multifocal presentation of urothelial cancer is well recognised. Concurrent bladder cancer impacts the outcome of the upper urinary tract urothelial cancer treatment, while its detection still relies on the white light cystoscopy. We retrospectively reviewed all patients who underwent photodynamic diagnostic ureterorenoscopy, choosing those who had synchronous bladder biopsies. Each patient received 20 mg/kg body weight of oral 5-Aminolevulinic acid around 3-4 hours before endoscopy. All procedures were performed by a single endourologist experienced in photodynamic diagnosis and flexible ureterorenoscopy. Between July 2009 and June 2013, 69 patients underwent bladder biopsies at the time of photodynamic diagnostic endoscopic inspection of the upper urinary tract. In total, 43.5% (30/69) patients were found to have bladder lesions, of which 43.3% (13/30) were proven to be carcinoma in situ. White light inspection of the bladder missed bladder cancer in 16 (23.1%) patients, of which 12 were carcinoma in situ. There were 14 bladder cancer lesions missed under white light which were concomitant to the upper urinary tract urothelial cancer. Twelve (17.4%) patients developed minor complications relevant to the photosensitizer. The study raises a concern about missing small bladder cancer/carcinoma in situ lesions on the initial diagnosis or in surveillance of the upper urinary tract urothelial cancer. Higher than previously reported, the rate of concomitant bladder cancer may suggest utilisation of photodynamic diagnosis to ensure the cancer free status of the bladder, but this needs to be ratified in a multi-institutional randomised trial.
- 1 January 2016
- Published by Polskie Towarzystwo Urologiczne in Central European Journal of Urology
- Vol. 69 (4) , 334-340
Open AccessConcurrent bladder cancer in patients undergoing photodynamic diagnostic ureterorenoscopy: how many lesions do we miss under white light cystoscopy?
There is an ongoing debate on panurothelial changes in the upper and lower urinary tract as multifocal presentation of urothelial cancer is well recognised. Concurrent bladder cancer impacts the outcome of the upper urinary tract urothelial cancer treatment, while its detection still relies on the white light cystoscopy. We retrospectively reviewed all patients who underwent photodynamic diagnostic ureterorenoscopy, choosing those who had synchronous bladder biopsies. Each patient received 20 mg/kg body weight of oral 5-Aminolevulinic acid around 3-4 hours before endoscopy. All procedures were performed by a single endourologist experienced in photodynamic diagnosis and flexible ureterorenoscopy. Between July 2009 and June 2013, 69 patients underwent bladder biopsies at the time of photodynamic diagnostic endoscopic inspection of the upper urinary tract. In total, 43.5% (30/69) patients were found to have bladder lesions, of which 43.3% (13/30) were proven to be carcinoma in situ. White light inspection of the bladder missed bladder cancer in 16 (23.1%) patients, of which 12 were carcinoma in situ. There were 14 bladder cancer lesions missed under white light which were concomitant to the upper urinary tract urothelial cancer. Twelve (17.4%) patients developed minor complications relevant to the photosensitizer. The study raises a concern about missing small bladder cancer/carcinoma in situ lesions on the initial diagnosis or in surveillance of the upper urinary tract urothelial cancer. Higher than previously reported, the rate of concomitant bladder cancer may suggest utilisation of photodynamic diagnosis to ensure the cancer free status of the bladder, but this needs to be ratified in a multi-institutional randomised trial.